Emerging class III antiarrhythmic agents: Mechanism of action and proarrhythmic potential

Cardiovascular Drugs and Therapy

Volumn 11, Issue 2, 1997, Pages 149-167

  Nair, Lawrence A ^a   Grant, Augustus O ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Class III antiarrhythmic agents; Delayed rectifier potassium channel; Use dependence

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; POTASSIUM CHANNEL; SOTALOL;

ACTION POTENTIAL; ARTICLE; HEART; HEART ARRHYTHMIA; HEART RATE; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; PRIORITY JOURNAL; REENTRY ARRHYTHMIA; TORSADE DES POINTES;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; HUMANS;

EID: 0030905460     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007784814823     Document Type: Article

References (140)

1. Kremers MS, Black WH, Wells PJ. Sudden cardiac death: Etiologies, pathologies, and treatment. Dis Month 1989; 35:391-445.
2. Fogoros R, Elson JJ, Bonnet CA, Fiedler SB, Burkholder JA. Efficacy of the automatic implantable cardioverter-defibrillator in prolonging survival in patients with severe underlying cardiac disease. J Am Coll Cardiol 1990;16:381-386.
3. Powell AC, Fuchs T, Finkelstein DM, et al. Influence of implantable cardioverter-defibrillators on the long-term prognosis of survivors of out-of-hospital cardiac arrest. Circulation 1993;88:1083-1092.
4. Echt DS, Lievson PR, Mitchell B, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. N Engl J Med 1991;324:781-788.
5. The Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992;327:227-233.
6. Mason JW. A comparison of electrophysiologic testing with Holter monitoring to predict antiarrhythmie-drug efficacy for ventricular tachyarrhythmias. N Engl J Med 1993;329: 445-451.
7. The CASCADE Investigators. Randomized antiarrhythmic drug therapy in survivors of cardiac arrest. Am J Cardiol 1993;72:280-287.
8. Burkart F, Pfisterer M, Kiowski W, Follath F, Burckhardt D. Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS). J Am Coll Cardiol 1990;16:1711-1718.
9. Ceremuzynski L, Kleczar E, Krzeminska-Pakula M, et al. Effect of amiodarone on mortality after myocardial infarction: A double-blind, placebo-controlled, pilot study. J Am Coll Cardiol 1992;20:1056-1062.
10. Cairns JA, Connolly SJ, Gent M, Roberts R. Post-myocardial infarction mortality in patients with ventricular premature depolarizations. Circulation 1991;84:550-557.
11. Pfisterer ME, Kiowski W, Brunner H, Burckhardt D, Burkart F. Long-term benefit of 1-year amiodarone treatment for persistent complex ventricular arrhythmias after myocardial infarction. Circulation 1993;87:309-311.
12. Zarembski DG, Nolan PE, Slack MK, Caruso AC. Empiric long-term amiodarone prophylaxis following myocardial infarction. Arch Intern Med 1993;153:2661-2667.
13. European Myocardial Infarction Amiodarone Trial (EMIAT). Paper presented at the American College of Cardiology, March 1996.
14. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial (CAMIAT). Paper presented at the American College of Cardiology, March 1996
15. Waldo AL, Camm AJ, de Ruyter H, et al. Preliminary mortality results from the Survival With Oral d-Sotalol (SWORD) trial (abstr). J Am Coll Cardiol 1995-25:15.
16. + currents in mammalian cardiac and glial cells. J Pharmacol Exp Ther 1990;254:560-569.
17. Fermini B, Wang Z, Duan D, Nattel S. Differences in rate dependence of transient outward current in rabbit and human atrium. Am J Physiol 1992;263:H1747-H1754.
18. Coraboeuf E, Carmeliet E. Existence of two transient outward currents in sheep cardiac purkinje fibers. Pflugers Arch 1982;392:352-359.
19. Tseng G, Hoffman BF. Two components of transient outward current in canine ventricular myocytes. Circ Res 1989;64:633-647.
20. Escande D, Couloumbe A, Faivre J, Deroubaix E, Coraboeuf E. Two types of transient outward currents in adult human atrial cells. Am J Physiol 1987;252:H142-H148.
21. Zygmunt AC, Gibbons WR. Calcium-activated chloride current in rabbit ventricular myocytes. Circ Res 1991;68:424-437.
22. Patlak JB, Ortiz M. Slow currents through single sodium channels of adult rat heart. J Gen Physiol 1985;86:89-104.
23. Kiehn J, Villena P, Beyer T, Brachmann J. Differential effects of the new class III agent dofetilide on potassium currents in guinea pig cardiomyocytes. J Cardiovasc Pharmacol 1994;24:566-572.
24. Noble D, Tseien RW. Outward membrane currents activated in the plateau range of potentials in cardiac purkinje fibres. J Physiol 1969;200:205-231.
25. Shirer A, Clay JR. Repolarization currents in embryonic chick atrial heart cell aggregates. Biophys J 1986;50:861-874.
26. + channel current. Circ Res 1993;73:210-216.
27. Wang Z, Fermini B, Nattel S. Delayed rectifier outward current and repolarization in human atrial myocytes. Circ Res 1993;73:276-285.
28. Wang Z, Fermini B, Nattel S. Rapid and slow components of delayed rectifier current in human atrial myocytes. Cardiovasc Res 1994;28:1540-1546.
29. + in single cardiac purkinje cells. Am J Physiol 1989; 257:C1086-C1092.
30. Kleiman RB, Houser SR. Outward currents in normal and hypertrophied feline ventricular myocytes. Am J Physiol 1989;256:H1450-H1461.
31. + current in single cardiac cells from bullfrog atrium. J Gen Physiol 1986;88:777-98.
32. Shimoni Y, Clark RB, Giles WR. Role of an inwardly rectifying potassium current in rabbit ventricular action potential. J Physiol 1992;448:709-27.
33. a properties. J Cardiovasc Electrophysiol 1994;5:711-21.
34. Moczydlowski E. Analysis of drug action at single-channel level. In: Rudy B, Iverson LE, eds. Methods in Enzymology, Vol. 207. San Diego, CA: Academic Press, 1992:791-806.
35. + current by almokalant in rabbit ventricular myocytes. Circ Res 1993;73:857-68.
36. Colquhoun D, Hawkes AG. The principles of the stochastic interpretation of ion-channel mechanisms. In: Sakmann G, Neher E, eds. Single Channel Recording. New York: Plenum, 1983:135-175.
37. Colatsky TJ, Follmer CH, Stramer CF. Channel specificity in antiarrhythmic drug action. Circulation 1990;82:2235-42.
38. + channel. Circ Res 1993;72:707-714.
39. Jurkiewicz NK, Sanguinetti MC. Rate-dependent prolongation of cardiac action potentials by a methanesulfonilide class III antiarrhythmic agent. Circ Res 1993;72:75-83.
40. Krafte DS, Volberg WA. Voltage dependence of cardiac delayed rectifier block by methanesulfonamide class III antiarrhythmic agents. J Cardiovasc Pharmacol 1994;23:37-41.
41. Ohler A, Amos GJ, Wettwer E, Ravens U. Frequency-dependent effects of E-4031, almokalant, dofetilide and tedisamil on action potential duration: No evidence for "reverse use dependent" block. Naunyn Schmiedebergs Arch Pharmacol 1994;349:602-610.
42. + current in rabbit ventricular myocytes. Cardiovasc Drugs Ther 1993;7:599-604.
43. Rasmussen HS, Allen MJ, Blackburn KJ, Butrous GS, Dalrymple HW. Dofetilide, a novel class III antiarrhythmic agent. J Cardiovasc Pharmacol 1992;20(Suppl 2):S96-S105.
44. Gwilt M, Blackburn KJ, Burges RA, Higgins AJ, Milne AA, Solca AM. Electropharmacology of dofetilide, a new class III agent, in anaesthetized dogs. Eur J Pharmacol 1992;215: 137-144.
45. Gwilt M, RC King, Milne AA, Solca AM. Dofetilide, a new class III antiarrhythmic agent, reduces pacing induced heterogeneity of repolarization in vivo. Cardiovasc Res 1992; 26:1102-1108.
46. Tham TCK. MacLennan BA, Burke MT, Harron DWG. Pharmacodynamics and pharmacokinetics of the class III antiarrhythmic agent dofetilide (UK-68, 798) in humans. J Cardiovasc Pharmacol 1993;21:507-512.
47. Sedgwick ML, Rasmussen HS, Cobbe SM. Clinical and electrophysiologic effects of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with angina pectoris. Am J Cardiol 1992;69:513-517.
48. Sedgwick ML, Rasmussen HS, Cobbe SM. Effects of the class III antiarrhythmic drug dofetilide on ventricular monophasic action potential duration and QT interval dispersion in stable angina pectoris. Am J Cardiol 1992;70:1432-1437.
49. Yuan S, Wohlfart B, Rasmussen HS, Olsson S, Blomstrom-Lundqvist C. Effect of dofetilide on cardiac repolarization in patients with ventricular tachycardia. Eur Heart J 1994;15:514-522.
50. Suttorp MJ, Polak PE, van't Hof A, Rasmussen HS, Dunselman PH, Kingma JH. Efficacy and safety of a new selective class III antiarrhythmic agent dofetilide in paroxysmal atrial fibrillation or atrial flutter. Am J Cardiol 1992;69:417-419.
51. Sedgwick ML, Lip G, Rae AP, Cobb SM. Chemical cardioversion of atrial fibrillation with intravenous dofetilide. Int J Cardiol 1195;49:59-166.
52. Bashir Y, Thomsen PEB, Kingma JH, et al. Electrophysiologic profile and efficacy of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with sustained monomorphic ventricular tachycardia. Am J Cardiol 1995;76:1040-1044.
53. Echt DS, Lee JT, Murray KT, et al. A randomized, double-blind, placebo-controlled, dose-ranging study of dofetilide in patients with inducible sustained ventricular tachyarrhythmias. J Cardiovasc Electrophysiol 1995;6:687-699.
54. + current. J Gen Physiol 1990;96:195-215.
55. Wettwer E, Scholtysik G, Schaad A, Himmel H, Ravens U. Effects of the new class III antiarrhythmic drug E-4031 on myocardial contractility and electrophysiological parameters. J Cardiovasc Pharmacol 1991;17:480-487.
56. Sanguinetti MC, Jurkiewicz NK, Scott A, Siegl PKS. Isoproterenol antagonizes prolongation of refractory period by the class III antiarrhythmic agent E-4031 in guinea pig myocytes. Circ Res 1991;68:77-84.
57. Martin CL, Chinn K. Contribution of delayed rectifier and inward rectifier to repolarization of the action potential: Pharmacologic separation. J Cardiovasc Pharmacol 1992; 19:830-837.
58. Chi L, Mu D, Lucchesi BR. Electrophysiology and antiarrhythmic actions of E-4031 in the experimental animal model of sudden coronary death. J Cardiovasc Pharmacol 1991;17:285-295.
59. Ogawa S, Mitamura H, Katoh H. Effect of E-4031, a new class III antiarrhythmic drug, on reentrant ventricular arrhythmias: Comparison with conventional class I drugs. Cardiovasc Drugs Ther 1993;7:621-626.
60. Lynch JJ, Heaney LA, Wallace AA, Gehret JR, Selnick HG, Stein RB. Suppression of lethal ischemic ventricular arrhythmias by the class III agent E-4031 in a canine model of previous myocardial infarction. J Cardiovasc Pharmacol 1990;15:764-775.
61. Adaniya H, Hiraoka M. Effects of a novel class III antiarrhythmic agent, E-4031, on reentrant tachycardias in rabbit right atrium. J Cardiovasc Pharmacol 1990;15:976-982.
62. Shimizu A, Kaibara M, Centurion OA, et al. Electrophysiologic effects of a new class III antiarrhythmic agent, E-4031, on atrial flutter, atrial refractoriness, and conduction delay in a canine sterile pericarditis model. J Cardiovasc Pharmacol 1993;21:656-662.
63. Inoue H, Yamashita T, Usui M, Nozaki A, Sugimoto T. Antiarrhythmic drugs preferentially produce conduction block at the area of slow conduction in the reentrant circuit of canine atrial flutter: Comparative study of disopyramide, flecainide, and E-4031. Cardiovasc Res 1991;25:223-229.
64. Shimizu A, Fukatani M, Konoe A, Isomoto S, Centurion OA, Yano K. Electrophysiological effects of a new class III antiarrhythmic agent (E-4031) on the conduction and refractoriness of the in vivo human atrium. Cardiovasc Res 1993;27:1333-1338.
65. Isomoto S, Shimizu A, Konoe A, et al. Electrophysiologic effects of E-4031, a new class III antiarrhythmic agent, in patients with supraventricular tachyarrhythmias. Am J Cardiol 1993;71:1464-1467.
66. Fujiki A, Tani M, Mizumaki K, Shimono M, Inoue H. Electrophysiologic effects of intravenous E-4031, a novel class III antiarrhythmic agent, in patients with supraventricular tachyarrhythmias. J Cardiovasc Pharmacol 1994;23:374-378.
67. Wettwer E, Grundke M, Ravens U. Differential effects of the new class III antiarrhythmic agents almokalant, E-4031, and d-sotalol, and of quinidine, on delayed rectifier currents in guinea pig ventricular myocytes. Cardiovasc Res 1992;26:1145-1152.
68. + current by almokalant in rabbit ventricular myocytes. Circ Res 1993;73:857-868.
69. Duker G, Almgren O, Carlsson L. Electrophysiologic and hemodynamic effects of H 234/09 (almokalant), quinidine, and (+)-sotalol in the anesthetized dog. J Cardiovasc Pharmacol 1992;20:458-465.
70. Wiesfeld ACP, Crijins JGM, Tobe TJM, et al. Electropharmacologic effects and pharmacokinetics of almokalant, a new class III antiarrhythmic, in patients with healed or healing myocardial infarcts and complex ventricular arrhythmias. Am J Cardiol 1992;70:990-996.
71. Sawanobori T, Adaniya H, Namiki T, Hiraoka M. Rate-dependent effects of sematilide on action potential duration in isolated guinea pig ventricular myocytes. J Pharmacol Exp Ther 1994;271:302-310.
72. Argentieri TM, Carroll MS, Sullivan ME. Cellular electrophysiological effects of the class III antiarrhythmic agents sematilide and clofilium on rabbit atrial tissues. J Cardiovasc Pharmacol 1991;18:167-174.
73. Chi LG, Mu DX Driscoll EM, Lucchesi BR. Antiarrhythmic and electrophysiologic actions of CK-3579 and sematilide in a conscious canine model of sudden coronary death. J Cardiovasc Pharmacol 1990;16:312-324.
74. Sager PT, Nademanee K, Antimisiaris M. Antiarrhythmic effects of selective prolongation of refractoriness. Electrophysiologic actions of sematilide HCL in humans. Circulation 1993;88:1072-1088.
75. Wong W, Pavlou HN, Birgersdotter UM, Hilleman DE, Mohiuddin SM, Roden DM Pharmacology of the class III antiarrhythmic agent sematilide in patients with arrhythmias. Am J Cardiol 1992;69:206-212.
76. Zhang Z, Follmer CH, Sarma JSM, Chen F, Singh BN. Effect of ambasilide, a new class III agent, on plateau currents in isolated guinea pig ventricular myocytes: Block of delayed outward potassium current. J Pharmacol Exp Ther 1992;263:40-48.
77. Takanaka C, Sarma JSM, Singh BN. Electrophysiologic effects of ambasilide (LU 47110), a novel class III antiarrhythmic agent, on the properties of isolated rabbit and canine cardiac muscle. J Cardiovasc Pharmacol 1992;19:290-298.
78. Wang J, Feng J, Nattel S. Class III antiarrhythmic drug action in experimental atrial fibrillation. Circulation 1994; 90:2032-2040.
79. Tatla DS, David BC, Malloy KJ, Moorehead TJ. In vitro electrophysiology of NE-10064, a novel and highly selective class III antiarrhythmic agent (abstr). FASEB J 1993; 7:A107.
80. McIntosh MA, Tanira M, Pacini D, Kane KA. Comparison of the cardiac electrophysiologic effects of NE-10064 with sotalol and E-4031 and their modification by simulated ischaemia. J Cardiovasc Pharmacol 1994;23:653-657.
81. Ks, in guinea pig cardiac myocytes. Biochem Biophys Res Commun 1994;202:265-270.
82. sK channel from neonatal rat heart and diethylstilbestrol-primed rat uterus. Proc Natl Acad Sci USA 1990;87:2975-2979.
83. sK channels expressed in Xenopus oocytes by the novel class III antiarrhythmic NE-10064. Eur J Pharmacol 1994;264:33-37.
84. Groh WJ, Gibson KJ, Maylie JG. Azimilide (NE-10064) prolongs action potential duration in a reverse rate-dependent manner in guinea pig ventricular muscle (abstr). PACE 1995;18(II):853.
85. Black SC, Butterfield JL, Lucchesi BR. Protection against programmed electrical stimulation-induced ventricular tachycardia and sudden cardiac death by NE-10064, a class III antiarrhythmic drug. J Cardiovasc Pharmacol 1993;22:810-818.
86. + currents in mammalian cardiac and glial cells. J Pharm Exp Ther 1990;254:560-569.
87. to blockade? J Cardiovasc Pharmacol 1991;18:445-456.
88. Bril A, Landais L, Gout B. Actions and interactions of E-4031 and tedisamil on reperfusion-induced arrhythmias and QT interval in rat in vivo. Cardiovasc Drugs Ther 1993;7:233-240.
89. Wallace AA, Stupienski RF, Baskin EP. Cardiac electrophysiologic and antiarrhythmic actions of tedisamil. J Pharmacol Exp Ther 1995;273:168-175.
90. Bargheer K, Bode F, Klein HU, Trappe HJ, Franz MR, Lichtlen PR. Prolongation of monophasic action potential duration and the refractory period in the human heart by tedisamil, a new potassium-blocking agent. Eur Heart J 1994;15:1409-1414.
91. + current acting as pure class III antiarrhythmic agents. J Cardiovasc Phamacol 1992;20(Suppl 2):S106-S113.
92. Nair LA, Grant AO. RP 58866 exhibits fast blocking kinetics of the inward-rectifying potassium channel (abstr). PACE 1995;18(II):234.
93. K1 blockade: A new antiarrhythmic mechanism? Circulation 1993;87:1979-1989.
94. Lee KS, Tsai TD, Lee EW. Membrane activity of class III antiarrhythmic compounds; a comparison between ibutilide, d-sotalol, E-4031, sematilide and dofetilide. Eur J Pharmacol 1993;234:43-53.
95. + current in guinea pig ventricular cells. J Pharmacol Exp Ther 1992;262:99-108.
96. Kr) in AT-1 cells. Circulation 1995;91:1799-1806.
97. Buchanan LV, Kabell G, Turcotte UM, Brunden MN, Gibson JK. Effects of ibutilide on spontaneous and induced ventricular arrhythmias in 24-hour canine myocardial infarction: A comparative study with sotalol and encainide. J Cardioasc Pharmacol 1992;19:256-263.
98. Wesley RC, Farkhani F, Morgan D, Zimmerman D. Ibutilide: Enhanced defibrillation via plateau sodium current activation. Am J Physiol 1993;264:H1269-H1274.
99. Buchanan LV, LeMay RJ, Gibson JK. Comparison of the class III agents d,l sotalol HCL and ibutilide fumarate for atrial reverse use dependence and antiarrhythmic effect (abstr). PACE 1996;19:687.
100. Buchanan LV, Turcotte UM, Kabell GG, Gibson JK. Antiarrhythmic and electrophysiologic effects of ibutilide in a chronic canine model of atrial flutter. J Cardiovasc Pharmacol 1993;22:10-14.
101. Nabih MA, Prcevski P, Fromm BS, et al. Effect of ibutilide, a new class III agent, on sustained atrial fibrillation in a canine model of acute ischemia and myocardial dysfunction induced by microembolization. PACE 1993;16:1975-1983.
102. Wood M, Stambler B, Gilligan D, et al. Suppression of inducible ventricular tachycardia by intravenous ibutilide in patients with coronary artery disease (abstr). PACE 1996; 19:618.
103. Stambler BS, Portnow AS, Wood MA, et al. Proven efficacy of repeated dose intravenous ibutilide, a class III antiarrhythmic drug, for rapid termination of chronic atrial flutter or fibrillation: Results of a multicenter placebo-controlled study (abstr). J Am Coll Cardiol 1995;25:230A.
104. Volgman AS, Stambler BS, Kappagoda C, et al. Comparison of intravenous ibutilide versus procainamide for the rapid termination of atrial fibrillation or flutter (abstr). PACE 1996;19:608.
105. Data on file, TR 1424-95-002. Kalamazoo, MI: The Upjohn Company.
106. Selzer A, Wray HW. Quinidine syncope. Circulation 1964; 30:17-26.
107. Hohnloser SH, Zabel M, van de Loo A, Klingenheben T, Just H. Efficacy and safety of sotalol in patients with complex ventricular arrhythmias. Int J Cardiol 1992;37:283-291.
108. Lazzara R. Amiodarone and torsade de pointes. Ann Intern Med 1989;111:549-550.
109. Mattioni TA, Zheutlin TA, Sarmiento JJ, Parker M, Lesch M, Kehoe RF. Amiodarone in patients with previous drug-mediated torsade de pointes. Ann Intern Med 1989;111:574-580.
110. Nguyen PT, Scheinman MM, Seger J. Polymorphous ventricular tachycardia: Clinical characterization, therapy, and the QT interval. Circulation 1986;74:340-349.
111. Bonatti V, Rolli A, Botti G. Recording of monophasic action potentials of the right ventricle in long QT syndromes complicated by severe ventricular arrhythmias. Eur Heart J 1983;4:168-179.
112. Bonatti V, Rolli A, Botti G. Monophasic action potential studies in human subjects with prolonged ventricular repolarization and long QT syndromes. Eur Heart J 1985;6(Suppl D):131-143.
113. January CT, Riddle JM. Early afterdepolarizations: Mechanisms of induction and block. Circ Res 1989;64:977-990.
114. 2+ channel agonist Bay K 8644. Circ Res 1988;62:563-571.
115. El-Sherif N, Zeiler RH, Craelius W, Gough WB, Henkin R. QTU prolongation and polymorphic ventricular tachyarrhythmias due to bradycardia-dependent early afterdepolarizations. Circ Res 1988;63:286-305.
116. Roden D. Early after-depolarizations and torsade de pointes: Implications for the control of cardiac arrhythmias by prolonging repolarization. Eur Heart J 1993;14(Suppl H):56-61.
117. Brachmann J, Scherlag BJ, Rosenshtraukh LV, Lazzara R. Bradycardia-dependent triggered activity: Relevance to drug-induced multiform ventricular tachycardia. Circulation 1983;68:846-856.
118. Rubart M, Pressler ML, Pride HP, Zipex DP. Electrophysiological mechanisms in a canine model of erythromycin-as-sociated long QT syndrome. Circulation 1993;88:832-844.
119. Carlsson L, Almgren O, Duker G. QTU-prolongation and torsades de pointes induced by putative class III antiarrhythmic agents in the rabbit: Etiology and interventions. J Cardiovasc Pharmacol 1990;16:276-285.
120. Roden DM, Hoffman BF. Action potentials prolongation and induction of abnormal automaticity by low quinidine concentrations in canine purkinje fibers. Circ Res 1985;56:857-867.
121. Strauss HC, Bigger JT, Hoffman BF. Electrophysiological and beta-receptor blocking effects of MJ 1999 on dog and rabbit cardiac tissue. Circ Res 1970;26:661-678.
122. Buchanan LV, Kabell G, Brunden MN, Gibson JK. Comparative assessment of ibutilide, d-sotalol, clofilium, E-4031, and UK-68,798 in a rabbit model of proarrhythmia. J Cardiovasc Pharmacol 1993;220:540-549.
123. K blocking drug UK-68,798: Potent in guinea pig but no effect in rat myocardium. J Cardiovasc Pharmacol 1990;16:401-410.
124. Sedgwick ML, Rasmussen HS, Cobbe SM. Effects of the class III antiarrhythmic drug dofetilide on ventricular monophasic action potential duration and QT interval dispersion in stable angina pectoris. Am J Cardiol 1992;70:1432-1437.
125. Carlsson L, Almgren O, Duker G. QTU-prolongation and torsades de pointes induced by putative class III antiarrhythmic agents in the rabbit: Etiology and interventions. J Cardiovasc Pharmacol 1990;16:276-285.
126. Carlsson L, Abrahamsson C, Andersson B, Duker G, Schiller-Linhardt G. Proarrhythmic effects of the class III agent almokalant: Importance of infusion rate, QT dispersion, and early afterdepolarizations. Cardiovasc Res 1993;27:2186-2193.
127. K blocking drugs, UK-68,798 (dofetilide) and E-4031. Cardiovasc Res 1993;27:861-867.
128. Wiesfeld ACP, Crijns HJGM, Bergstrand RH, Almgren O, Hillege HL, Lie KI. Torsades de pointes with almokalant, a new class III antiarrhythmic drug. Am Heart J 1993;126:1008-1011.
129. Ellenbogen K, Vanderlugt J, Robbins I, Kowey P, for the Ibutilide Investigators. Overall safety experience with intravenous ibutilide (abstr). PACE 1996;19:608.
130. Campbell RM, Woosley RL, Iansmith DHS, Roden DM. Lack of triggered automaticity despite repolarization abnormalities due to bepridil and lidoflazine. PACE 1990;13:30-6.
131. Li ZY, Maldonado C, Zee-Cheng C, Hiromasa S, Kupersmith J. Purkinje fibre-papillary muscle interaction in the genesis of triggered activity in a guinea pig model. Cardiovasc Res 1992;26:543-548.
132. Antzelevitch C, Sicouri S. Clinical relevance of cardiac arrhythmias generated by afterdepolarizations. The role of M cells in the generation of U waves, triggered activity and torsade de pointes. J Am Coll Cardiol 1994;23:259-277.
133. Sicouri S, Antzelevitch C. Electrophysiologic characteristics of M cells in the canine left ventricular free wall. J Cardiovasc Electrophysiol 1995;6:591-603.
134. Sicouri S, Antzelevitch C. Afterdepolarizations and triggered activity develop in a select population of cells (M cells) in canine ventricular myocardium. The effects of acetylstrophanthidin and Bay K 8644. PACE 1991;14:1714-1720.
135. Sicouri S, Antzelevitch C. Drug-induced afterdepolarizations and triggered activity occur in a discrete subpopulation of ventricular muscle cell (M cells) in the canine heart. Quinidine and digitalis. J Cardiovasc Electrophysiol 1993;4:48-58.
136. Balser JR, Bennett PB, Hondeghem LM, Roden DM. Suppression of time-dependent outward current in guinea pig ventricular myocytes. Circ Res 1991;69:519-529.
137. Sager PT, Uppal P, Follmer C, Antimisiaris M, Pruitt C, Singh BN. Frequency-dependent electrophysiologic effects of amiodarone in humans. Circulation 1993;88:1063-1071.
138. Krafte DS, Dugrenier N, Dillon K, Volberg WA. Electrophysiological properties of a cloned, human potassium channel expressed in xenopus oocytes (abstr). Biophys J 1992; 61:A378.
139. + currents in isolated human ventricular myocytes from patients with terminal heart failure. Circ Res 1993;73:379-385.
140. Veldkamp MW, van Ginneken ACG, Opthof T, Bouman LN. Delayed rectifier channels in human ventricular myocytes. Circulation 1995;92:3497-3504.